secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001104659-25-001665
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma closes $20M public offering; net proceeds ~$18.3M
----------------------------------------------------------------

- Gross proceeds ~$20M from 40M common units at $0.50/unit (1 share + 1 Series A + 1 Series B warrant).
- Net proceeds after underwriting fees ~$18.3M; over-allotment added 6M Series A and 6M Series B warrants.
- Funds expected to support operations through 2025 and advance ABP-450 biosimilar development.
- After offering, shares outstanding ~79.97M; warrants exercisable at $0.625/share post-stockholder approval.
- CEO Marc Forth highlighted sufficient capital for 351(k) regulatory pathway and planned BPD Type 2 meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000110465925001665/0001104659-25-001665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000110465925001665/tm2432042d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-001665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer